{"filing":{"accession_number":"0001104659-26-084095","cik":"0001802665","ticker":"HRMY","company_name":"Harmony Biosciences Holdings, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"hrmy-20260716x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716x8k.htm"},"events":[{"id":18311,"run_id":16459,"accession_number":"0001104659-26-084095","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Harmony Biosciences disclosed preliminary Q2 2026 net product revenue of approximately $261 million for WAKIX, representing a record quarterly result with 30% year-over-year growth, and reaffirmed full-year 2026 net revenue guidance of $1.0–$1.04 billion.","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17080,"accession_number":"0001104659-26-084095","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses preliminary Q2 2026 net product revenue of approximately $261 million for WAKIX, representing a record quarterly result with 30% year-over-year growth, and reaffirms full-year 2026 net revenue guidance of $1.0–$1.04 billion. This is a classic earnings preannouncement via press release attached as Exhibit 99.1, disclosing material financial results that would affect a reasonable investor's assessment of the company's performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17082,"accession_number":"0001104659-26-084095","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing announces that Chief Financial Officer Glenn Reicin \"has stepped down to pursue other opportunities, effective July 16, 2026,\" with Stephen Mollichella appointed as Interim Principal Financial Officer. While the press release also discloses record Q2 2026 revenue and reaffirmed full-year guidance (earnings-related content), the Item 7.01 section specifically references \"officer changes discussed above,\" making the CFO departure the principal event disclosed in this Item. The departure of a CFO is material to investors assessing management continuity and financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18312,"run_id":16459,"accession_number":"0001104659-26-084095","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Chief Financial Officer Glenn Reicin departed effective July 16, 2026 to pursue other career opportunities, with Stephen Mollichella appointed as Interim Principal Financial Officer.","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17081,"accession_number":"0001104659-26-084095","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Glenn Reicin's departure as Chief Financial Officer effective July 16, 2026 is the primary disclosed action. While the filing also announces Stephen Mollichella's appointment as Interim Principal Financial Officer, the prose centers on Reicin's stepping down \"to pursue other career opportunities\" and the severance arrangement. The CFO departure is material to investors assessing leadership continuity and financial oversight, though the appointment of an interim successor and the company's strong financial performance (record Q2 revenue, reaffirmed guidance) mitigate some concern.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17082,"accession_number":"0001104659-26-084095","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing announces that Chief Financial Officer Glenn Reicin \"has stepped down to pursue other opportunities, effective July 16, 2026,\" with Stephen Mollichella appointed as Interim Principal Financial Officer. While the press release also discloses record Q2 2026 revenue and reaffirmed full-year guidance (earnings-related content), the Item 7.01 section specifically references \"officer changes discussed above,\" making the CFO departure the principal event disclosed in this Item. The departure of a CFO is material to investors assessing management continuity and financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17080,"accession_number":"0001104659-26-084095","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses preliminary Q2 2026 net product revenue of approximately $261 million for WAKIX, representing a record quarterly result with 30% year-over-year growth, and reaffirms full-year 2026 net revenue guidance of $1.0–$1.04 billion. This is a classic earnings preannouncement via press release attached as Exhibit 99.1, disclosing material financial results that would affect a reasonable investor's assessment of the company's performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-07-16"},{"id":17081,"accession_number":"0001104659-26-084095","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Glenn Reicin's departure as Chief Financial Officer effective July 16, 2026 is the primary disclosed action. While the filing also announces Stephen Mollichella's appointment as Interim Principal Financial Officer, the prose centers on Reicin's stepping down \"to pursue other career opportunities\" and the severance arrangement. The CFO departure is material to investors assessing leadership continuity and financial oversight, though the appointment of an interim successor and the company's strong financial performance (record Q2 revenue, reaffirmed guidance) mitigate some concern.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-07-16"},{"id":17082,"accession_number":"0001104659-26-084095","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing announces that Chief Financial Officer Glenn Reicin \"has stepped down to pursue other opportunities, effective July 16, 2026,\" with Stephen Mollichella appointed as Interim Principal Financial Officer. While the press release also discloses record Q2 2026 revenue and reaffirmed full-year guidance (earnings-related content), the Item 7.01 section specifically references \"officer changes discussed above,\" making the CFO departure the principal event disclosed in this Item. The departure of a CFO is material to investors assessing management continuity and financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:36:44.052444+00:00","company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","filing_date":"2026-07-16"}]}